In preclinical experiments, highly potent antibodies against MMP-14 catalytic domain were found to be efficient in inhibiting MMP-14-mediated tumor development and metastasis, indicating that targeting MMP-14 is a viable therapeutic approach [84]. This evidence concerns the gene MMP14 and neoplasm.